How Long Can You Live After Heart Valve Replacement?

Most people who undergo heart valve replacement live for many years afterward, and for a sizable group the procedure restores something close to a normal life expectancy. A large Swedish registry study found that the average loss in life expectancy after surgical aortic valve replacement was about two years across all ages, and for patients over 80 the gap shrank to less than half a year. Those numbers vary considerably depending on which valve is replaced, the type of prosthesis used, the patient’s age and overall health, and whether surgery is open-chest or catheter-based. The real answer is not a single number but a range shaped by decisions made before, during, and after the operation.

Aortic Valve Replacement and the Big-Picture Numbers

The aortic valve is the most commonly replaced heart valve, so it has the deepest pool of long-term data. The SWEDEHEART registry tracked thousands of patients who had surgical aortic valve replacement and compared their survival to the general Swedish population. Across the whole group, 19-year survival was about 21 percent, versus 34 percent for a matched general population, translating to a relative survival of roughly 63 percent. In practical terms, the average patient lost about two years of life expectancy compared with someone of the same age who never needed the operation.¹

Age at surgery shapes the picture dramatically. Patients younger than 50 lost an estimated four and a half years of life expectancy, while those 80 and older lost less than half a year. That pattern makes intuitive sense: an older person’s remaining lifespan is shorter to begin with, so there is less room for the valve disease to chip away at it. A separate study confirmed the trend, reporting that patients over 75 who survived the initial hospital stay had survival rates essentially identical to the general population at one, five, and eight years.²

Mechanical Valves Versus Bioprosthetic Valves

The two main categories of replacement valve are mechanical and bioprosthetic. Mechanical valves are made from durable synthetic materials and can last a lifetime, but they require you to take a blood thinner, typically warfarin, every day for the rest of your life. That commitment is not trivial. Warfarin requires regular blood monitoring, and it carries a persistent risk of serious bleeding, including in the brain and the gastrointestinal tract.³

Bioprosthetic valves are made from animal tissue, usually pig or cow. They do not require lifelong blood thinners in most cases, which is a major quality-of-life advantage. The trade-off is durability: tissue valves gradually calcify and stiffen over time, and many will need to be replaced or treated again. How quickly that happens depends heavily on your age at implantation. In patients over 70 who received bioprosthetic aortic valves, roughly 93 percent were free from structural failure and reoperation at 15 years. In patients between 61 and 70, that number dropped to about 71 percent.⁴ The younger you are, the faster your body breaks down the biological tissue.

Because of that age-dependent wear, younger patients have traditionally been steered toward mechanical valves despite the anticoagulation burden, while older patients often receive bioprosthetics. That calculus is shifting as catheter-based options make it easier to treat a worn-out tissue valve without full open-heart surgery, but the fundamental trade-off between durability and daily medication remains.

Open Surgery Compared with Catheter-Based Replacement

Transcatheter aortic valve replacement, or TAVR, was originally developed for patients too frail for open-chest surgery. It involves threading a compressed valve through a blood vessel and expanding it into place inside the heart. The procedure has expanded rapidly into lower-risk populations, raising the question of how its long-term results compare with traditional surgical replacement.

Ten-year data from the OBSERVANT study, which matched TAVR and surgical patients by risk profile, found that survival after open surgery was roughly double that of TAVR at the decade mark: about 37 percent versus 18 percent. The survival curves started to diverge around year three and stayed apart.⁵ An extended analysis of the same registry confirmed that TAVR carried a roughly 39 percent higher risk of death over ten years compared with surgery.⁶

Those numbers need context. The OBSERVANT patients were treated in the early 2010s, and TAVR technology has improved considerably since then. A contemporary review concluded that structural deterioration of TAVR valves may actually be lower than that of surgical bioprostheses at the five-to-ten-year mark, and that overall valve failure rates appear similar between the two approaches.⁷ In short, open surgery still has the strongest long-term survival data, but the gap with TAVR may narrow as newer-generation devices accumulate follow-up.

Mitral Valve Repair Versus Replacement

For the mitral valve, surgeons prefer repair over replacement whenever technically possible, and the survival data explain why. A large international registry following patients for 20 years found that survival after mitral valve repair was about 46 percent at the two-decade mark, compared with roughly 23 percent after replacement. Operative mortality was also substantially lower with repair.⁸

When repair is done successfully for degenerative mitral valve disease, patients can expect a lifespan that matches the general population. A study tracking post-repair patients across a wide age range found that their additional life expectancy was statistically indistinguishable from that of healthy Americans of the same age, and for patients between 50 and 89 there was even a slight survival advantage, likely reflecting selection bias and close medical follow-up.⁹

Repair is not always an option. When the mitral valve is damaged by coronary artery disease rather than by degenerative wear, repair and replacement produce similar survival rates at one year, but the repaired valve is more likely to leak again: about a third of repair patients had significant regurgitation return within 12 months, compared with just a couple of percent after replacement.¹⁰ The cause of the valve disease matters enormously in determining which approach gives you the best outcome.

The Ross Procedure for Younger Adults

For younger adults with aortic valve disease, the Ross procedure offers a different path. The surgeon removes the diseased aortic valve and replaces it with the patient’s own pulmonary valve, then places a donor valve in the pulmonary position. Because the transplanted valve is living tissue from your own body, it avoids both the anticoagulation demands of a mechanical valve and the accelerated calcification that plagues bioprosthetics in younger people.

The survival advantage is striking. A meta-analysis found that patients who underwent the Ross procedure had roughly half the death rate of those who received a mechanical valve.¹¹ A single-center study reported 20-year survival of 95 percent for Ross patients versus 68 percent for mechanical valve recipients; even after propensity matching to account for differences in patient health, the Ross group still showed 94 percent survival versus 84 percent.¹² The Ross procedure also carried substantially lower rates of stroke and bleeding.

The catch is that the Ross procedure has a higher reintervention rate: about 76 percent higher than mechanical valves in the meta-analysis. The pulmonary valve placed in the aortic position can dilate over the years, and the donor valve in the pulmonary position can also deteriorate. So the procedure does not guarantee freedom from future operations. It does, however, seem to offer the best shot at a long, medication-free life for patients in their twenties, thirties, and forties.

What Happens When a Bioprosthetic Valve Wears Out

If you receive a bioprosthetic valve in your fifties or sixties, there is a reasonable chance you will outlive it. When that happens, you face a choice: undergo open-heart surgery again, which carries higher risk the second time around, or have a new catheter-based valve placed inside the old one, a procedure called valve-in-valve TAVR.

A literature review of studies comparing the two approaches found that short-term outcomes tend to favor the catheter-based route, with fewer immediate complications like heart attack and atrial fibrillation. But redo open surgery may offer better survival over the medium and long term in some patient groups.¹³ One propensity-matched study found that redo surgery had better five-year survival than valve-in-valve TAVR (about 62 percent versus 47 percent), and this advantage held across patients with both lower and higher comorbidity burdens.¹⁴ Another study found comparable one-year survival between the two, though valve-in-valve patients had more heart-failure readmissions.¹⁵

The bottom line for patients planning decades ahead is that wearing out a bioprosthetic valve is not a dead end, but the second procedure carries its own risks and trade-offs. If you are young enough that you will likely need two or three valves over a lifetime, that chain of procedures becomes part of the longevity equation.

When the Replacement Valve Does Not Fit Right

One underappreciated factor in post-replacement survival is prosthesis-patient mismatch, which happens when the replacement valve’s effective opening is too small relative to the patient’s body size. The heart has to work harder to push blood through an undersized valve, and that extra strain accumulates over the years.

A meta-analysis covering more than 27,000 patients found that prosthesis-patient mismatch raised the risk of death by about a third overall. When mismatch was severe, the risk nearly doubled.¹⁶ A more recent study put numbers on the ten-year gap: roughly 43 percent of patients without mismatch had died by year ten, compared with 48 percent of those with severe mismatch, with higher rates of heart failure hospitalization in the severe group.¹⁷ In the early postoperative period, severe mismatch was linked to dramatically higher mortality risk.¹⁸

This is partly a surgical planning issue. Experienced centers aim to implant the largest valve that fits safely, or they use techniques to enlarge the valve seat. Patients with a smaller body size, especially shorter women, are at higher risk of mismatch and should ask their surgical team how they plan to address it.

How the Heart Recovers After Surgery

Replacing a faulty valve removes the mechanical burden on the heart, and in many patients the thickened or stretched heart muscle begins to remodel back toward a more normal size and shape. That recovery process turns out to be a meaningful predictor of how long you live afterward. A study using cardiac MRI found that patients whose heart muscle mass regressed significantly after aortic valve surgery had substantially better outcomes than those whose hearts did not remodel.¹⁹ Research on patients with leaky aortic valves and enlarged hearts found the same pattern: failure to remodel predicted worse long-term events.²⁰

What makes this clinically relevant is timing. Echocardiographic measurements taken one year after valve replacement are more strongly linked to long-term survival than the measurements taken before surgery.²¹ That one-year check-in is not just routine; it is genuinely prognostic. If your heart has remodeled well, your outlook is better. If it has not, there may be an opportunity to intervene earlier with medications or closer monitoring.

Sex Differences in Valve Surgery Outcomes

Women have historically had higher short-term mortality after open surgical aortic valve replacement, partly because they tend to present for surgery at an older age and with more coexisting health problems. Interestingly, women who receive bioprosthetic aortic valves have significantly better long-term survival than men, roughly half the hazard of death in one large study. That advantage disappeared with mechanical aortic valves, where survival was similar between sexes, though women faced a higher stroke risk.²²

For catheter-based replacement, the picture flips in an encouraging way: no difference in 30-day mortality between men and women, and women actually appear to have better longer-term survival after TAVR than men.²³ For mitral valve surgery, women are less likely to receive repair over replacement, and while unadjusted survival after repair looked worse for women, the difference disappeared after accounting for baseline health. However, mitral repair restored life expectancy for men but not for women in one large Medicare study.²⁴

Tricuspid Valve Replacement

Most valve replacement data focus on the left side of the heart, but the tricuspid valve on the right side sometimes needs replacement too, most commonly in patients with severe congestive heart failure, prior heart surgery, or intravenous drug use. Outcomes are generally worse than for aortic or mitral replacements. A study of tricuspid valve replacement found ten-year survival of about 45 percent with bioprosthetic valves and 59 percent with mechanical valves.²⁵ In-hospital mortality was around 20 percent in a smaller series, and advanced fluid retention, particularly ascites, was a strong predictor of not surviving the operation.²⁶ Tricuspid replacement is a higher-stakes procedure because the patients who need it tend to be sicker, and the right side of the heart operates under different pressure dynamics than the left.

Infection of a Prosthetic Valve

Prosthetic valve endocarditis is one of the most feared complications after valve replacement. An infection on a prosthetic valve is harder to treat than one on a native valve and carries steep mortality. In one multicenter study, about 21 percent of patients with prosthetic valve endocarditis died during the initial hospitalization, and another 26 percent of survivors died over the following roughly three years. The strongest predictors of death were Staphylococcus aureus infection and severe heart failure.²⁷

A reassuring finding from the Swedish registry, however, is that patients who survive the first 30 days after surgery for prosthetic valve endocarditis have long-term survival roughly similar to those who had surgery for a native valve infection.²⁸ The high-risk window is early. Good dental hygiene, prompt treatment of infections, and antibiotic prophylaxis before certain procedures are the practical steps patients can take to reduce the risk.

Socioeconomic Factors and Survival Gaps

Survival after valve replacement is not determined by biology alone. Socioeconomic status exerts a measurable and persistent influence. A Swedish study found that patients in the lowest income bracket had about a 36 percent higher risk of death compared with the highest, and those with less than ten years of education had roughly a 20 percent higher risk than the most educated group. The gap between the most and least socioeconomically advantaged patients translated to nearly three years of median survival difference.²⁹

A UK study found similar patterns, with the most deprived patients having 15-year survival rates roughly 7 to 18 percentage points lower than the least deprived, depending on sex.³⁰ These gaps likely reflect differences in access to follow-up care, medication adherence, rehabilitation participation, and the management of other chronic conditions. Community-level economic distress has also been linked to worse outcomes after aortic valve replacement.³¹

Depression and Mental Health After Surgery

Depression before valve surgery is more than a quality-of-life concern; it independently predicts whether you survive the first six months. A study of valve surgery patients found that those who were depressed preoperatively had roughly twice the odds of dying within six months, even after adjusting for age, lung disease, hypertension, and kidney function. The association held whether the surgery was aortic, mitral, or combined with bypass.³²

Cognitive changes after heart surgery are also common. A systematic review found that structured cognitive training reduced the rate of postoperative cognitive problems from about 50 percent to 19 percent at hospital discharge, and from 29 percent to 6 percent at three months.³³ If your hospital offers a cognitive rehabilitation program before or after surgery, it is worth taking seriously.

Cardiac Rehabilitation and Physical Function

Your physical condition after surgery matters for longevity in a direct, measurable way. A randomized trial of early cardiac rehabilitation after valve surgery found that physical function, measured by a simple test of standing balance, walking speed, and ability to rise from a chair, was the only significant predictor of mortality among the variables studied. Higher physical function scores correlated with higher survival rates.³⁴

A systematic review of exercise-based rehabilitation after aortic valve procedures found that the existing studies have not yet demonstrated a direct effect on death rates or hospitalizations, largely because the trials are small and follow-up periods short.³⁵ But the indirect evidence is compelling: physical function predicts survival, and rehabilitation improves physical function. Most cardiac surgery centers now recommend structured rehabilitation, and patients who participate tend to recover faster and feel better.

What Patients Actually Die From After Valve Replacement

It is worth understanding that a replaced valve does not make the heart invincible. The SWEDEHEART registry tracked causes of death over a mean of about seven years after surgical aortic valve replacement. At ten years, cardiovascular causes accounted for about 24 percent of deaths, cancer for about 8 percent, and other causes for roughly 12 percent. The cancer death rate was no different from what you would expect in the general population, meaning the surgery itself does not appear to add cancer risk. But cardiovascular death remained elevated compared with the general population, with a standardized mortality ratio of about 1.8.³⁶ That elevated cardiovascular risk reflects the fact that many valve patients have underlying heart disease or risk factors that do not disappear just because the valve has been fixed.

Emerging Valve Technology

The biggest limitation of current bioprosthetic valves is calcification, the gradual buildup of calcium deposits that stiffens the leaflets and eventually causes failure. Researchers are attacking this problem from multiple angles. One approach involves improved tissue-treatment techniques that have shown significantly reduced calcification in animal models compared with the standard chemical fixation method used today.³⁷ Another line of research uses nanoparticle coatings to attach drugs directly to valve tissue, targeting clotting, inflammation, and calcification simultaneously. Early results in animal models showed reduced calcification and clotting without altering how the valve opens and closes.³⁸ These are still in preclinical stages, but if they translate to humans, the next generation of tissue valves could last meaningfully longer, which would reshape the calculus for younger patients deciding between valve types.